#USA #Cranford #LYMPHIR #Citius Oncology #Cencora

Citius Oncology Expands Distribution Network for LYMPHIR

Citius Oncology, Inc. has made a significant stride in its commercial launch strategy for LYMPHIR by entering a distribution services agreement with Cencora, a global pharmaceutical services provider. This strategic partnership is designed to enhance Citius Oncology's distribution capabilities and ensure that the FDA-approved immunotherapy is accessible to patients suffering from relapsed or refractory cutaneous T-cell lymphoma (CTCL).

Enhancing Commercial Infrastructure

The recent agreement is a crucial part of Citius Oncology's plan to expand its commercial distribution network for LYMPHIR. With Cencora’s reputation as a leader in specialty pharmaceutical distribution, this partnership aims to facilitate broader market access and increase product availability across the United States. By enhancing their commercial infrastructure, Citius Oncology is working diligently towards achieving readiness for the imminent market introduction of LYMPHIR.

Leonard Mazur, the Chairman and CEO of Citius Oncology and Citius Pharmaceuticals, stated, "As we move closer to the U.S. market introduction of LYMPHIR, we remain focused on disciplined execution across all key commercial readiness activities. Our agreement with Cencora adds further depth to our distribution strategy and strengthens our ability to deliver LYMPHIR to treatment centers across the country. These foundational partnerships demonstrate our ongoing commitment to building a launch platform that supports near-term revenue and long-term shareholder value."

LYMPHIR: A Pioneering Immunotherapy

LYMPHIR (denileukin diftitox-cxdl) is a pioneering therapeutic option for patients diagnosed with relapsed or refractory CTCL. As a targeted immune therapy, it is indicated for use in patients with Stage I-III disease who have undergone at least one prior systemic therapy. The mechanism of action involves binding to IL-2 receptors on the cell surface, which initiates a cascade that ultimately leads to cell death in cancerous T-cells.

The agent has demonstrated notable efficacy by not only depleting immunosuppressive regulatory T lymphocytes but also exhibiting direct antitumor activity. Regulatory approval of LYMPHIR was granted by the FDA in August 2024, following its successful development and evaluation in clinical trials.

Understanding Cutaneous T-Cell Lymphoma

CTCL is a type of non-Hodgkin lymphoma that manifests primarily through skin lesions, significantly affecting the quality of life of those afflicted. Patients suffering from CTCL often endure chronic symptoms, including severe pain and discomfort, which lead to a diminished quality of life. The illness sees a higher prevalence in men, particularly those aged between 50 and 60 years, and is characterized by the malignant transformation of T-cells.

Due to the disease’s complexity, treatment regimens typically involve the use of multiple agents to manage symptoms and progression. Unfortunately, there is currently no curative therapy available for advanced CTCL aside from allogeneic stem cell transplantation, which is not an option for many patients.

Looking Forward

The distribution agreement with Cencora marks a pivotal point for Citius Oncology as they gear up for the market launch of LYMPHIR. This collaboration is expected to bolster the company's ability to deliver its innovative therapy to the healthcare facilities and patients who need it, ultimately aiming to improve treatment outcomes in the fight against CTCL. As the company forges ahead, it remains committed to rigorous execution and establishing a solid commercial foundation that fosters growth and patient-centric solutions in oncology.